TerminatedNCT02088060
A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol As a Treatment for Acutely Ill Schizophrenic Patients
Medication studyAges 18–65Denmark + GermanySchizophrenia
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- Glostrup Municipality and 5 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: December 8, 2015
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 150
- Sponsor
- Central Institute of Mental Health, Mannheim
- Sponsor type
- Research institute
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Denmark, Germany
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT02088060
- Official title
Show the full official title
A Four-week, Multicentre, Double-blinded, Randomised, Active- and Placebo- Controlled, Parallel-group Trial Investigating Efficacy and Safety of Cannabidiol in Acute, Early-stage Schizophrenic Patients
Recruitment & locations
TerminatedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Glostrup Municipality, Denmark · Heidelberg, Germany · Mannheim, Germany
2 more locations
- Munich, Germany
- Halle, Germany
Questions about this study
Who is behind this study?
The study sponsor is Central Institute of Mental Health, Mannheim, a research institute.
Does this study involve medication?
Yes. The study involves medication, including Cannabidiol, Olanzapine, Placebo Cannabidiol and Placebo Olanzapine.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as terminated.
